Cleveland Clinic’s Stanley Hazen, M.D., Ph.D., Recognized as 2017 Distinguished Scientist by The American Heart Association

Stanley Hazen, M.D., Ph.D., chair of the Department of Cellular & Molecular Medicine in the Lerner Research Institute and section head of Preventive Cardiology & Rehabilitation in the Miller Family Heart & Vascular Institute at Cleveland Clinic, has been named by the American Heart Association (AHA) a Distinguished Scientist for 2017.

Stanley L. Hazen, M.D., Ph.D., chair of Cellular and Molecular Medicine

According to the AHA, the Distinguished Scientist designation was created in 2003 to honor AHA/ASA members who have made extraordinary contributions to cardiovascular and stroke research. This title recognizes influential research that has importantly advanced the understanding, management, and treatment of cardiovascular disease or stroke.

“Dr. Hazen’s research has fundamentally changed the way we think about the role of diet and the microbiome in the pathogenesis of heart disease.” said Serpil Erzurum, M.D., chair of Cleveland Clinic’s Lerner Research Institute. “Dr. Hazen is highly deserving of this distinguished award. We have already seen how his findings can change care. We look forward to watching his research continue to advance, and to see how his work will impact human health and patient care.”

“I am honored and humbled to receive this recognition from the AHA,” said Dr. Hazen. “I also want to acknowledge and thank my colleagues who have helped and supported me in making the discoveries and advances over the years.”

Dr. Hazen has published more than 380 peer-reviewed articles in basic and clinical journals alike. He has made pioneering discoveries in atherosclerosis and inflammatory disease research, including the seminal discovery linking gut microbial pathways to cardiovascular disease (CVD) and metabolic diseases, including atherosclerosis, thrombosis, heart failure and chronic kidney disease. His research impacts clinical practice, and lays the foundation for FDA-cleared diagnostic tests, and ongoing CVD drug development efforts.

In a recent landmark study, Dr. Hazen showed that interfering with certain gut microbial pathways with therapeutics can help block diet-dependent atherosclerosis. His comprehensive work establishes a new understanding of diet/gut microbe/host interactions in diseases and has spawned development of both new diagnostic tests and therapeutic approaches for the treatment and prevention of cardiovascular diseases and metabolic disorders.

Hazen’s numerous other discoveries include defining pathways white blood cells use to generate reactive oxidants and their functional importance in heart disease.

A member of Cleveland Clinic’s staff since 1997, Dr. Hazen is both a practicing physician and researcher and holds many leadership roles at Cleveland Clinic. He holds the Jan Bleeksma Chair in Vascular Cell Biology and Atherosclerosis.

He has received numerous awards, including election to the American Federation for Medical Research, the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine. He is also a fellow of the American Association for the Advancement of Science.

Dr. Hazen is the first Cleveland Clinic staff physician to receive this honor.  He is among a class of seven scientists to be recognized at the annual American Heart Association Scientific Sessions.

Dr. Hazen earned a bachelor’s degree and dual M.D. /Ph.D. degree in Biophysical Chemistry and Molecular Biology, along with clinical training in Internal Medicine with subspecialty in Diabetes, Endocrinology and Metabolism at Washington University School of Medicine, St Louis.

 

 

About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Among Cleveland Clinic’s 51,000 employees are more than 3,500 full-time salaried physicians and researchers and 14,000 nurses, representing 140 medical specialties and subspecialties. Cleveland Clinic’s health system includes a 165-acre main campus near downtown Cleveland, 10 regional hospitals, more than 150 northern Ohio outpatient locations – including 18 full-service family health centers and three health and wellness centers – and locations in Weston, Fla.; Las Vegas, Nev.; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2016, there were 7.1 million outpatient visits, 161,674 hospital admissions and 207,610 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.

 

Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.

 

About the Lerner Research Institute

The Lerner Research Institute is home to Cleveland Clinic’s laboratory, translational and clinical research. Its mission is to promote human health by investigating in the laboratory and the clinic the causes of disease and discovering novel approaches to prevention and treatments; to train the next generation of biomedical researchers; and to foster productive collaborations with those providing clinical care. Lerner researchers publish more than 1,500 articles in peer-reviewed biomedical journals each year.  Lerner’s total annual research expenditure was $260 million in 2016 (with $140 million in competitive federal funding, placing Lerner in the top five research institutes in the nation in federal grant funding). Approximately 1,500 people (including approximately 200 principal investigators, 240 research fellows, and about 150 graduate students) in 12 departments work in research programs focusing on heart and vascular, cancer, brain, eye, metabolic, musculoskeletal, inflammatory and fibrotic diseases. The Lerner has more than 700,000 square feet of lab, office and scientific core services space. Lerner faculty oversee the curriculum and teach students enrolled in the Cleveland Clinic Lerner College of Medicine (CCLCM) of Case Western Reserve University – training the next generation of physician-scientists. Institute faculty also participate in multiple doctoral programs, including the Molecular Medicine PhD Program, which integrates traditional graduate training with an emphasis on human diseases. The Lerner is a significant source of commercial property, generating 64 invention disclosures, 15 licenses, 121 patents, and one new spinoff company in 2016. Visit us at www.lerner.ccf.org. Follow us on Twitter at www.twitter.com/CCLRI.